Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Navarixin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 known ✓ | P25025 | 20/20 | 1.00 |
| ▸ | CXCR1 known ✓ | P25024 | 17/20 | 1.00 |
| ▸ | CCR7 | P32248 | 3/20 | 1.00 |
| ▸ | CCR6 | P51684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Navarixin Anhydrous SCHEMBL1446663 | 1.00 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL12262719 | 1.00 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL2024683 | 0.99 | CXCR2 (0.98) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL2024684 | 0.99 | CXCR2 (0.98) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12263105 | 0.90 | CXCR2 (0.81) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12087147 | 0.90 | CXCR2 (0.81) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262817 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL248562 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12574856 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262770 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1036 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099526-A1 | COMBINATION OF INHIBITORS OF IL-1BETA, CCR5 OR CXCR2 CYTOKINE RECEPTORS FOR USE IN THE TREATMENT OF METASTASIS | FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2026-05-15 | — | — | WO | claimed |
| EP-4686472-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE | Dompé farmaceutici SpA (IT) | 2026-02-04 | — | — | EP | claimed |
| EP-4686469-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF DIABETES-ASSOCIATED COMORBIDITIES | Dompé farmaceutici SpA (IT) | 2026-02-04 | — | — | EP | claimed |
| EP-4678171-A1 | SYSTEMICALLY-ADMINISTERED CXCL8 INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompé farmaceutici SpA (IT) | 2026-01-14 | — | — | EP | claimed |
| US-20250376522-A1 | Targeting Cells with a Combination of CXCR2 Inhibition and CD47 Blockade | UNIV LELAND STANFORD JUNIOR (US) | 2025-12-11 | — | — | US | claimed |
| EP-4646193-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompé farmaceutici S.p.A. (IT) | 2025-11-12 | — | — | EP | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025151629-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH INFLAMMATION, PAIN AND/OR LESIONS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250222109-A1 | STRUCTURED LIPID COMPOSITIONS | THE UNIVERSITY OF BERN (CH) | 2025-07-10 | — | — | US | claimed |
| EP-4563594-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF TUMORS WITH LOW STROMAL CAV1 LEVELS | Dompe' Farmaceutici SpA (IT) | 2025-06-04 | — | — | EP | claimed |
| EP-3316886-B1 | METHODS AND COMPOUNDS FOR THE ALLEVIATION AND/OR PREVENTION OF PAIN | SVENSSON CAMILLA (SE) | 2022-05-18 | — | — | EP | claimed |
| EP-3277719-B1 | POLYPEPTIDES | SORRISO PHARMACEUTICALS INC (US) | 2022-03-16 | — | — | EP | claimed |
| US-20220062260-A1 | COMBINATION THERAPY FOR TREATMENT OF LKB1 DEFICIENT CANCERS | NEW YORK UNIVERSITY | 2022-03-03 | — | — | US | claimed |
| US-10940126-B2 | Inhibition of IL-8 in the treatment of pain and/or bone loss | SVENSSON CAMILLA (SE) | 2021-03-09 | — | — | US | claimed |
| US-20190248876-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2019-08-15 | — | — | US | claimed |
| US-20170181987-A1 | INHIBITION OF IL-8 IN THE TREATMENT OF PAIN AND/OR BONE LOSS | SVENSSON CAMILLA (SE) | 2017-06-29 | — | — | US | claimed |
| US-20160168233-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | NEW YORK UNIVERSITY | 2016-06-16 | — | — | US | claimed |
| US-20130231393-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-09-05 | — | — | US | claimed |
| EP-2588092-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | Galderma Research & Development (FR) | 2013-05-08 | — | — | EP | claimed |
| WO-2012001076-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231393-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | AQP3, SUCNR1, AQP1 | CXCR2 3127/4885CXCR1 1617/4885CCR7 2877/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CXCR2 1756/4885CXCR1 3248/4885CCR7 2365/4885 |
| US-20190248876-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | CXCR2 2/4885CXCR1 1/4885CCR7 14/4885 |
| US-20160168233-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | CXCR2 2/4885CXCR1 1/4885CCR7 14/4885 |
| US-20250222109-A1 | STRUCTURED LIPID COMPOSITIONS | FABP2, MGLL, LIPC | CXCR2 1119/4885CXCR1 1696/4885CCR7 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.